Opens in a new tab
Monday, 16 November 2026
EVIDENCE. INTERPRETED.
Pharmacally

Hidradenitis Suppurativa

Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.

Advertisement · Remove ads
970 × 90

Latest in Hidradenitis Suppurativa

7 stories · every one Fact-Checked
AbbVie lutikizumab Phase 3 INTREPID trial results for hidradenitis suppurativa, highlighting improvements in skin pain and disease flares.Clinical TrialsAbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis SuppurativaAbbVie’s Phase 3 INTREPID trial met its primary endpoint for investigational lutikizumab in moderate-to-severe hidradenitis suppurativa.23 Oct 2026 · 4 min read
Fact-Checked
Tulisokibart Phase 2b study results in moderate to severe hidradenitis suppurativaClinical TrialsTulisokibart Meets Phase 2b Endpoint in Hidradenitis SuppurativaMerck’s investigational anti-TL1A antibody tulisokibart met the primary endpoint in a Phase 2b hidradenitis suppurativa study, with HiSCR50 responses of up to 72% at week 16.1 Oct 2026 · 4 min read
Fact-Checked
MoonlakeClinical TrialsMoonLake Reports Strong One-Year Phase 3 Results for Sonelokimab in Hidradenitis SuppurativaMoonLake Immunotherapeutics reported durable one-year Phase 3 data for sonelokimab in moderate-to-severe hidradenitis suppurativa, showing 67.2% HiSCR75 response rates, meaningful quality-of-life improvements, and no new safety signals.22 Jun 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_8t1a5q8t1a5q8t1aHealth TidingsMoonLake Aligns with FDA on BLA Strategy for SLK in Hidradenitis SuppurativaMoonLake Immunotherapeutics said the FDA supported key elements of its planned BLA submission for sonelokimab in hidradenitis suppurativa, including efficacy analyses, adolescent patient inclusion, and safety data strategy.…10 May 2026 · 3 min read
Fact-Checked
Gemini_Generated_Image_sorfz2sorfz2sorfHealth TidingsAvalo Reports Positive Phase 2 Results for Abdakibart in HSThe Phase 2 LOTUS trial met its primary endpoint, with abdakibart demonstrating statistically significant HiSCR75 improvements and favorable safety findings in adults with moderate to severe hidradenitis suppurativa.7 May 2026 · 3 min read
Fact-Checked
(c)Yves FonckHealth TidingsBIMZELX Shows Durable Remission in Psoriasis and Sustained 3-Year Control in Hidradenitis Suppurativa at AAD 2026New BIMZELX data presented at AAD 2026 highlight high rates of sustained skin clearance in psoriasis and long-term flare control in hidradenitis suppurativa, reinforcing its durability across indications.29 Mar 2026 · 3 min read
Fact-Checked
Incyte_logo.svgClinical TrialsIncyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis SuppurativaPovorcitinib showed sustained clinical responses and improved quality of life through 54 weeks in Phase 3 Hidradenitis Suppurativa trials, with regulatory reviews ongoing in the U.S. and Europe.29 Mar 2026 · 3 min read
Fact-Checked
Page 1 of 1